Cargando…
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097817/ https://www.ncbi.nlm.nih.gov/pubmed/33947460 http://dx.doi.org/10.1186/s13195-021-00828-1 |
_version_ | 1783688389576359936 |
---|---|
author | Aichholzer, Freyja Klafki, Hans-Wolfgang Ogorek, Isabella Vogelgsang, Jonathan Wiltfang, Jens Scherbaum, Norbert Weggen, Sascha Wirths, Oliver |
author_facet | Aichholzer, Freyja Klafki, Hans-Wolfgang Ogorek, Isabella Vogelgsang, Jonathan Wiltfang, Jens Scherbaum, Norbert Weggen, Sascha Wirths, Oliver |
author_sort | Aichholzer, Freyja |
collection | PubMed |
description | BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson’s disease patients. METHODS: The present study describes the partial “fit for purpose” validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF). We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively. RESULTS: The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels. CONCLUSIONS: The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00828-1. |
format | Online Article Text |
id | pubmed-8097817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80978172021-05-05 Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease Aichholzer, Freyja Klafki, Hans-Wolfgang Ogorek, Isabella Vogelgsang, Jonathan Wiltfang, Jens Scherbaum, Norbert Weggen, Sascha Wirths, Oliver Alzheimers Res Ther Research BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson’s disease patients. METHODS: The present study describes the partial “fit for purpose” validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF). We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively. RESULTS: The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels. CONCLUSIONS: The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00828-1. BioMed Central 2021-05-04 /pmc/articles/PMC8097817/ /pubmed/33947460 http://dx.doi.org/10.1186/s13195-021-00828-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Aichholzer, Freyja Klafki, Hans-Wolfgang Ogorek, Isabella Vogelgsang, Jonathan Wiltfang, Jens Scherbaum, Norbert Weggen, Sascha Wirths, Oliver Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title | Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title_full | Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title_fullStr | Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title_full_unstemmed | Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title_short | Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease |
title_sort | evaluation of cerebrospinal fluid glycoprotein nmb (gpnmb) as a potential biomarker for alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097817/ https://www.ncbi.nlm.nih.gov/pubmed/33947460 http://dx.doi.org/10.1186/s13195-021-00828-1 |
work_keys_str_mv | AT aichholzerfreyja evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT klafkihanswolfgang evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT ogorekisabella evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT vogelgsangjonathan evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT wiltfangjens evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT scherbaumnorbert evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT weggensascha evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease AT wirthsoliver evaluationofcerebrospinalfluidglycoproteinnmbgpnmbasapotentialbiomarkerforalzheimersdisease |